The prevalence of vitamin D deficiency in people with inflammatory bowel disease (IBD) varies from 16% to 95% and it is usually more frequent in Crohn's disease (CD) than in ulcerative colitis (UC) (3) . A recent meta-analysis showed that the prevalence is also greater than that found in a healthy population (4) . Prevalence data on vitamin D deficiency in patients with IBD are scarce in Spain (5) . A few observational, heterogeneous or cross-sectional studies have attempted to determine the association between vitamin D deficiency and clinical and prognostic variables of IBD (clinical disease activity, quality of life, hospitalization or need for surgery). However, no regular association has been found (6) . Furthermore, different clinical indexes and systemic biological parameters of activity have been used, such as C reactive protein (CRP). Only three studies included fecal calprotectin (FC) as a more sensitive parameter of inflammatory activity (7) (8) (9) .
The possible relationship between quality of life and vitamin D deficiency in patients with IBD has not been clarified, as the results from various studies are discordant (10, 11) . In addition, patients with IBD have an increased risk of anxiety and depression (12) . A few observational studies have detected an association between vitamin D deficiency and depression, as well as a possible therapeutic role for vitamin D in this situation (13) . However, no data are available with regard to the possible association between IBD, anxiety-depression and vitamin D.
The main aim of the study was to determine the prevalence of vitamin D deficiency in a series of outpatients with IBD from a hospital in southern Spain and examine the association with clinical and biological parameters, including FC. The secondary endpoint was to assess the association between vitamin D concentration and quality of life related to health and psychological symptoms.
MATERIAL AND METHODS
This cross-sectional, observational study was performed in a third-level hospital in 
Patients
The study comprised consecutive outpatients older than 18 years of age with a diagnosis of IBD (UC and CD) according to standard criteria (14) , who were able to understand and complete the information form and health questionnaires. The exclusion criteria included the following: associated coeliac disease or short bowel syndrome, treatment with non-steroidal anti-inflammatory drugs during the previous month, liver or kidney failure, pregnancy or lactation, and cases undergoing antiepileptic treatment. The consumption of vitamin D supplements was not a reason for exclusion. At the time of study inclusion, the indexes of clinical activity were calculated and the clinical and demographic variables were recorded. The completed questionnaires (quality of life and psychological symptoms) were collected one week after study inclusion and a blood sample was taken at the same time. The laboratory measurements included those routinely used for outpatient follow-up plus the determination of 25OHD and FC. The patients were classified according to the Montreal classification (15) .
Evaluation of vitamin D levels
Serum 25OHD was quantified by an electro-chemiluminescence immunoassay (Cobas® e602, Roche, Switzerland). Levels of 25OHD < 20 ng/ml were considered as deficient;
20-29.9 ng/ml, as insufficient; and ≥ 30 ng/ml, as adequate, in accordance with the criteria of the Endocrine Society (16) . The season when the measurement was taken was also noted; winter was considered to be from November until April and summer from May until October. Patients were considered as having vitamin D supplements if they had received daily treatment with at least 800 IU of vitamin D during the last month.
Evaluation of IBD activity, physical activity, quality of life and psychological symptoms
The clinical activity was assessed using the Harvey-Bradshaw index (HBI) for patients with CD and the Partial Mayo score for patients with UC. A CRP ≥ 10 mg/dl was considered as pathological (17) . The FC was measured via an ELISA (Calprest® Eurospital, Trieste, Italy). The Calprest values ranged from 15.6 mcg/g to 500 mcg/g.
Samples with values > 500 mcg/g were subsequently diluted to obtain values above 1,000 mcg/g. In agreement with a recent study from our latitude and using the same FC commercial technique (18) , 170 mcg/g was used as the cut point to differentiate between the biological viewpoint and active disease and remission. Quality of life was measured using the Spanish version of the Short Quality of Life in Inflammatory Bowel
Disease Questionnaire (SIBDQ-9). Psychological symptoms were assessed using the Hospital Anxiety and Depression scale (HADS). The level of physical activity was assessed with the international physical activity questionnaire (IPAQ) and the results were calculated in METS (multiples of the basal metabolic rate) (42) . 
Statistical analysis

Ethical considerations
The study protocol was approved by the Provincial Research Ethics Committee of Malaga. The data were recorded anonymously in a coded electronic database. The project complies with the principles of the Declaration of Helsinki and the norms of good clinical practice.
RESULTS
Patients: clinical and demographic data
Initially, 289 consecutive outpatients with IBD who were regularly followed-up by our service were invited to participate in the study. Of these, 40 were not included for the final analysis. The reasons for exclusion included: refusal to participate (n = 10), age < 18 years (n = 4), language barrier or inability to read and understand the questionnaires (n = 10), short bowel (n = 2), gestation or lactation (n = 3), use of nonsteroidal anti-inflammatory drugs (n = 4), alteration of the liver profile (n = 2), associated coeliac disease (n = 1), kidney failure (n = 3) and treatment with antiepileptic drugs (n = 1). Of the remaining 249 patients, 25 were excluded as they had no laboratory measurements. Thus, the final study included 224 patients (150 with CD and 74 with UC). However, 75 patients failed to complete all the questionnaires on quality of life, physical activity and psychological symptoms. Accordingly, the sub analysis of these variables was performed with 149 patients (107 CD and 42 UC). Table   1 shows the main clinical and demographic characteristics.
Prevalence of vitamin D deficiency
The prevalence of vitamin D deficiency and insufficiency (95% confidence interval) in the entire series was 29% ( However, a seasonal effect was noted, with a lower mean 25OHD in winter months than summer months for both CD (21.53 ± 9.22 ng/nl vs 29.11 ± 11.93 ng/ml, p < 0.001) and UC (26.51 ± 11.11 vs 34.76 ± 9.6, p < 0.001). In addition, the proportion of patients with vitamin D deficiency was greater in winter than in summer for both CD (48.5% vs 21.4%; p < 0.001) and UC (35.2% vs 6%; p = 0.002).
Associations between 25OH vitamin D and clinical and demographic variables
Tables 2-4 summarize the association between the demographic variables and the clinical and biological parameters according to the concentration of 25OHD of the entire patient cohort, the CD cohort and the UC cohort, respectively.
Demographic variables, smoking and body mass index
No association was found between the 25OHD concentration and age, duration of disease, active smoking or body mass index (BMI). The proportion of male UC patients with a 25OHD deficiency was significantly lower than for female UC patients (p = 0.02).
Clinical activity and biological parameters
The (Fig. 2) . Likewise, in patients with UC, the mean 25OHD was significantly lower in patients with FC > 170 mcg/g than in those with lower values (23.04 ± 10.34 ng/ml vs 32.14 ± 10.68 ng/ml; p = 0.004) (Fig. 3) . No significant differences were found in the median and mean 25OHD levels between the patients with CRP values above or below 10 mg/l in CD or UC.
Inflammatory bowel disease phenotype (Montreal classification) and prior surgery
The patients with CD who had previously undergone surgery had a lower median 
DISCUSSION
This study highlights the high prevalence of insufficient vitamin D concentrations in outpatients with IBD in our area. This finding was particularly notable in patients with CD, with a joint prevalence of 68% (33.3% deficiency). This prevalence rate in CD is almost exactly the same as that found by Raferty in 119 Irish patients with CD (8). It is also similar to that reported for a North American population (19) and lower than that seen in a recent multicenter Norwegian study (53% deficiency) (7) . There are few data available for patients with UC, with prevalence rates ranging from 15% to 44% (7, 20) .
Thus in agreement with our findings. On the other hand, we found a significantly lower median vitamin D concentration in CD compared to UC. This was not found by the various studies analyzing this issue (21, 22) .
A Spanish population-based study on the prevalence of hypovitaminosis D (which used the same methodology as we did) included over 1,200 non-institutionalized patients with no chronic diseases that affected phosphocalcium metabolism (40). Just over half the patients resided in the province where the study was undertaken. The prevalence of vitamin D deficiency (< 20 ng/ml) was almost the same (33.9%) as that observed in CD in our study. The lack of important differences in the proportion of vitamin D deficiency between healthy people and CD patients was also described by De Bruyn et al. in a case-control study in a Dutch population (34) . The similar prevalence rates can be explained by the fact that most of the patients included were in clinical remission, had mild activity and the mean age of the patients in the Spanish population-based study (a risk factor for deficiency in their study) was 50 years of age. In addition, the seasonal effect was evident, with significantly higher vitamin D values in summer, although the deficiency prevalence in winter months in our study in CD patients (48.5%) was higher (37.2%) (40).
A cross-sectional study that was also undertaken in Spain examined the relation between vitamin D deficiency and bone mineral density in 64 patients with CD. There was a deficiency prevalence of 60% (5). However, the reduced sample size and the absence of information about the season during which the measurements were taken or the percentage of patients with clinical activity hindered a comparison with our findings. In our study, as in other similar studies (22, 28) , the season the measurements were taken conditioned the results. There were significantly greater 25OHD
concentrations when the samples were measured in the summer. Likewise, the percentage of patients with 25OHD concentrations below 20 ng/ml were greater in winter, for both UC and CD. This difference in seasonality has not been seen by others at different latitudes (7, 11) . Various cross-sectional studies have suggested an association between deficient vitamin D serum concentrations and a greater clinical and biological activity in CD and UC, although, overall, data are inconsistent (4,6).
These studies differ greatly in terms of design, method of measuring 25OHD, composition of the study population and the clinical indexes and biological parameters of activity used.
In our patients, vitamin D deficiency was significantly associated with the presence of clinical activity in CD and UC, as measured by the HBI and Partial Mayo score. This aspect is discordant among the various studies, as some indicate an association with the CDAI (24), HBI (7) or the simple ulcerative colitis index (25) , whereas others fail to show this association (8, 23) . In an attempt to correct the subjective component of the clinical indexes, we divided the patients according to FC and CRP levels. The median and the mean 25OHD in CD and UC, respectively, were greater in the groups considered to be non-active according to the FC criteria (< 170 mcg/g). This same finding was reported in another study on CD (8) which used a higher cut point for FC
(250 mcg/g).
There is a general lack of an association between the vitamin D concentration and the CRP (7, 8, 11, 26) , although the occasional study did find a significant association (24) .
This may be due to the inclusion of few active patients and the lack of an increase in CRP in many patients with endoscopy-demonstrated activity. Our study identified a significant association between the CRP concentration and the vitamin D level in the entire cohort but not in the individual groups of patients with UC or CD separately. FC has been shown to be better than CRP and clinical disease activities at discriminating intestinal inflammation, with a good correlation with endoscopic and histological scoring systems for IBD (27) . Garg et al. (9) found a negative correlation between the 25OHD concentration and FC levels in 40 patients with CD. An Irish study detected a gradient in the FC concentration between the different subgroups of patients according to their vitamin D levels (8) . We also noted this situation in the entire cohort of 224 patients and in the patients with CD, but not in UC cases. Only two studies have detected an association between vitamin D deficiency and FC levels in UC (7, 9) .
The association between vitamin D deficiency and some of the phenotypic characteristics of CD varies. The patients in our study with CD who had previously undergone surgery had significantly lower concentrations of 25OHD than the patients who had not undergone surgery. Moreover, lower 25OHD levels were found in the ileum compared to the colon. This finding has been noted in other studies (22, 29, 30 ).
In addition, our patients with a fistulising pattern had significantly lower levels than those with an inflammatory or stenotic pattern.
Quality of life has been associated with 25OHD concentration (10,21) and one study even identified an improvement in quality of life after repletion of levels above 30 ng/ml (31) . Given the relationship between vitamin D and depression and anxiety seen in some observational studies (12), we wanted to include this factor in our study.
However, neither quality of life (assessed with the SIBDQ-9) nor the psychological symptoms (evaluated with the HADS) were associated with the 25OHD concentration in our series.
Kabani et al. performed a prospective study involving 965 patients with IBD and found a significant association between vitamin D deficiency levels and a greater consumption of health resources (32) . We found an association with the use of steroids in the previous six months and hospitalization in the last year, although only in UC patients. A few other variables have been associated with low levels of vitamin D in IBD. Notable among these are longstanding disease (36) , age (19, 32) , sex, smoking (33, 34) , steroid use, obesity (35) and non-Caucasian race (22, 35) . As the great majority of patients in our series were Caucasian, we are unable to assess this aspect. Neither the presence of active smoking, a greater BMI, nor a longer disease duration were associated with vitamin D levels in our study. Furthermore, no association was detected between the vitamin D status and biological therapy or treatment with immunosuppressive drugs or steroids. However, recent studies have suggested a possible contribution of adequate vitamin D levels to the durability of biological treatment (37, 38) .
This study has a few limitations. Firstly, the cross-sectional nature of the study makes it impossible to draw conclusions regarding causality. Other limitations include the fact that it was a single-center study and there was no group of healthy controls.
Furthermore, the gold standard for the measurement of vitamin D, liquid chromatography/tandem mass spectrometry, was not used in this study (39) .
However, the electro-chemiluminescence immunoassay method used is nevertheless the most widely employed and applicable in the clinical practice. Furthermore, it is calibrated with international standards. There may also have existed a certain degree of selection bias, as the outpatients from a regional reference hospital were more complex. The study population was almost solely Caucasian, which makes it impossible to compare our findings with those of other cohorts with a greater ethnic variation.
Another possible bias that is not contemplated in most studies is the influence of the clinical activity on the lower physical exercise and thus, a reduced possibility of solar exposure. The sub-analysis of 149 patients in our series showed no significant differences in the median scores on the IPAQ between active patients and patients in remission. This can mainly be explained by the fact that the study involved active outpatients, mostly with mild or mild-to-moderate activity, who were able to carry out similar physical exercises to the patients in remission. Thus, we do not consider that physical activity has influenced the results.
The strengths of the study relate to the inclusion of a large and representative number of outpatients in follow-up for IBD and the prospective collection of the clinical data by the same team of IBD specialists. In addition, the difference with regard to seasonal measurements of vitamin D was also studied and FC was used as a more sensitive marker of clinical activity than CRP or indexes of clinical activity that are commonly used.
In conclusion, both deficient and insufficient levels of vitamin D are prevalent in IBD outpatients in our health area and there was a notable association with a greater 
